MCID: EST002
MIFTS: 44

Estrogen-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Negative Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Negative Breast Cancer:

Name: Estrogen-Receptor Negative Breast Cancer 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0060076

Summaries for Estrogen-Receptor Negative Breast Cancer

MalaCards based summary : Estrogen-Receptor Negative Breast Cancer is related to estrogen-receptor positive breast cancer and breast cancer. An important gene associated with Estrogen-Receptor Negative Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Glioma and Gastric cancer. The drugs Bevacizumab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and lymph node, and related phenotypes are growth/size/body region and endocrine/exocrine gland

Related Diseases for Estrogen-Receptor Negative Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 estrogen-receptor positive breast cancer 29.7 ERBB2 ESR1 FOXA1 PGR
2 breast cancer 28.2 AR BRCA1 EGF ERBB2 ESR1 FOXA1
3 vulvar syringoma 10.9 ESR1 PGR
4 lung leiomyoma 10.9 ESR1 PGR
5 vestibular gland benign neoplasm 10.9 ESR1 PGR
6 bartholin's gland adenoma 10.9 ESR1 PGR
7 vulvar benign neoplasm 10.8 ESR1 PGR
8 scirrhous adenocarcinoma 10.8 ERBB2 PGR
9 trigonitis 10.8 ESR1 PGR
10 breast apocrine carcinoma 10.8 ERBB2 PGR
11 vulvar leiomyoma 10.8 ESR1 PGR
12 comedo carcinoma 10.8 ERBB2 ESR1
13 predominantly cortical thymoma 10.8 ESR1 PGR
14 postmenopausal atrophic vaginitis 10.8 AR ESR1
15 breast mucoepidermoid carcinoma 10.8 ERBB2 PGR
16 breast metaplastic carcinoma 10.8 ERBB2 PGR
17 intracystic papillary adenoma 10.8 ERBB2 PGR
18 progesterone resistance 10.8 ESR1 PGR
19 progesterone-receptor negative breast cancer 10.8 ERBB2 PGR
20 cribriform carcinoma 10.8 ESR1 PGR
21 gastric signet ring cell adenocarcinoma 10.8 ESR1 PGR
22 endometrial mucinous adenocarcinoma 10.8 ESR1 PGR
23 sebaceous adenoma 10.8 EGF ESR1
24 adenoid basal cell carcinoma 10.8 ESR1 PGR
25 bartholin's gland benign neoplasm 10.7 ESR1 PGR
26 deep angioma 10.7 ESR1 PGR
27 calcifying aponeurotic fibroma 10.7 EGF PGR
28 corneal abscess 10.7 AR PGR
29 cervical carcinosarcoma 10.7 ESR1 PGR
30 uterine body mixed cancer 10.7 ERBB2 PGR
31 estrogen excess 10.7 ESR1 PGR
32 breast squamous cell carcinoma 10.7 ERBB2 PGR
33 intramuscular hemangioma 10.6 ESR1 PGR
34 mammographic density 10.6 ESR1 PGR
35 endometrial squamous cell carcinoma 10.6 AR ESR1 PGR
36 glassy cell carcinoma of the cervix 10.6 ERBB2 ESR1 PGR
37 gender identity disorder 10.6 AR ESR1 PGR
38 retinitis pigmentosa 47 10.6 ESR1 PGR
39 epispadias 10.6 EGF ERBB2
40 breast scirrhous carcinoma 10.6 ERBB2 ESR1 PGR
41 progesterone-receptor positive breast cancer 10.6 ERBB2 ESR1 PGR
42 microglandular adenosis 10.6 ERBB2 PGR
43 uterine corpus cancer 10.6 ERBB2 ESR1 PGR
44 paget disease, extramammary 10.6 AR ERBB2
45 breast benign neoplasm 10.6 ERBB2 ESR1 PGR
46 thoracic benign neoplasm 10.6 ERBB2 ESR1 PGR
47 inflammatory breast carcinoma 10.6 ERBB2 ESR1 PGR
48 mixed cell type cancer 10.6 ERBB2 ESR1 PGR
49 gynecomastia 10.6 AR ESR1 PGR
50 lipid-rich carcinoma 10.6 ERBB2 ESR1 PGR

Graphical network of the top 20 diseases related to Estrogen-Receptor Negative Breast Cancer:



Diseases related to Estrogen-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Negative Breast Cancer

MGI Mouse Phenotypes related to Estrogen-Receptor Negative Breast Cancer:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.16 PTPRA WNT5A ETS1 FOXA1 ESR1 CCAR2
2 endocrine/exocrine gland MP:0005379 10.13 WNT5A ETS1 FOXA1 PGR ESR1 EGF
3 homeostasis/metabolism MP:0005376 10.13 PTPRA WNT5A ETS1 FOXA1 PGR BRCA1
4 immune system MP:0005387 10.06 WNT5A ETS1 FOXA1 PGR ESR1 CCAR2
5 digestive/alimentary MP:0005381 10.05 WNT5A FOXA1 ESR1 EGF AR ERBB2
6 embryo MP:0005380 10.04 PGR WNT5A ETS1 BRCA1 ESR1 AR
7 integument MP:0010771 9.97 ETS1 FOXA1 PGR ESR1 EGF AR
8 limbs/digits/tail MP:0005371 9.8 WNT5A PGR ESR1 AR ERBB2 BRCA1
9 muscle MP:0005369 9.73 PGR ESR1 WNT5A BRCA1 AR ERBB2
10 neoplasm MP:0002006 9.7 FOXA1 PGR CCAR2 AR ERBB2 BRCA1
11 normal MP:0002873 9.5 PGR WNT5A BRCA1 ESR1 EGF AR
12 reproductive system MP:0005389 9.17 PGR ESR1 WNT5A BRCA1 EGF AR

Drugs & Therapeutics for Estrogen-Receptor Negative Breast Cancer

Drugs for Estrogen-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Not Applicable 216974-75-3
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
3
Docetaxel Approved, Investigational Phase 3,Not Applicable 114977-28-5 148124
4
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
5
Fluorouracil Approved Phase 3 51-21-8 3385
6
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
7
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
8
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
9
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
10
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3 33069-62-4 36314
11
Goserelin Approved Phase 3 65807-02-5 47725 5311128
12
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
13
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
14
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
15
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
16
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
19
Lapatinib Approved March 2007, Investigational Phase 3 231277-92-2, 388082-78-8 208908 9941095
20
Doxil Approved June 1999 Phase 3,Phase 2 31703
21 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 Angiogenesis Inhibitors Phase 3,Phase 2,Not Applicable
23 Angiogenesis Modulating Agents Phase 3,Phase 2,Not Applicable
24 Anti-Bacterial Agents Phase 3,Phase 2
25 Antibiotics, Antitubercular Phase 3,Phase 2
26 Antimetabolites Phase 3,Phase 2
27 Antimetabolites, Antineoplastic Phase 3,Phase 2
28 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
29 Antirheumatic Agents Phase 3,Phase 2,Not Applicable
30 Estrogens Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
32 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
34 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
35 Progestins Phase 3,Phase 2,Phase 1,Not Applicable
36 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
37 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
38 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3
39 Anti-Infective Agents Phase 2, Phase 3
40 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
41 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
42 Antiviral Agents Phase 2, Phase 3
43 Antineoplastic Agents, Hormonal Phase 3,Phase 2
44 Dermatologic Agents Phase 3,Phase 2
45 Folic Acid Antagonists Phase 3,Phase 2
46 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
47 Vitamin B Complex Phase 3,Phase 2
48 triamcinolone acetonide Phase 3
49 Triamcinolone diacetate Phase 3
50 Triamcinolone hexacetonide Phase 3

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
2 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Unknown status NCT01104571 Phase 3 lapatinib ditosylate
3 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed NCT01881230 Phase 2, Phase 3 nab-Paclitaxel;Carboplatin;Gemcitabine
4 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
5 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
6 Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer Completed NCT00022516 Phase 3 Cyclophosphamide;Methotrexate
7 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
8 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer Recruiting NCT01805076 Phase 3
9 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
10 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
11 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
12 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Unknown status NCT01037790 Phase 2 PD-0332991
13 Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer Completed NCT00239343 Phase 2 gefitinib
14 Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer Completed NCT00577122 Phase 2 Medroxyprogesterone progesterone acetate (MPA);Medroxyprogesterone with Cyclophosphamide + Methotrexate
15 Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Completed NCT00559507 Phase 2 saracatinib
16 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
17 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
18 Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer Completed NCT01105312 Phase 1, Phase 2 letrozole;panobinostat
19 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
20 Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer Completed NCT00834678 Phase 1, Phase 2 bendamustine;erlotinib;Maintenance erlotinib
21 Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery Completed NCT00424203 Phase 2 AC regimen;cyclophosphamide;doxorubicin hydrochloride
22 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer Recruiting NCT01471106 Phase 2 Dasatinib
23 Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer Recruiting NCT02315196 Phase 2 pegylated liposomal doxorubicin hydrochloride;epirubicin hydrochloride;carboplatin;paclitaxel
24 Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
25 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer Active, not recruiting NCT00733408 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation;erlotinib hydrochloride
26 Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Active, not recruiting NCT01818063 Phase 2 Paclitaxel;Carboplatin;Doxorubicin;Cyclophosphamide;Veliparib
27 Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients Active, not recruiting NCT01372579 Phase 2 eribulin mesylate;carboplatin
28 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer Active, not recruiting NCT01463072 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
29 Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery Active, not recruiting NCT01147016 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
30 GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Terminated NCT01918306 Phase 1, Phase 2 cisplatin;GDC -0941
31 Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery Terminated NCT01234532 Phase 2 entinostat;anastrozole
32 RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Terminated NCT01217411 Phase 1, Phase 2 Gamma-secretase/Notch signalling pathway inhibitor RO4929097
33 Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer Terminated NCT01151449 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
34 Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer Withdrawn NCT01100489 Phase 2
35 Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery Withdrawn NCT01612910 Phase 2 oral microencapsulated diindolylmethane
36 Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
37 Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer Completed NCT01104259 Phase 1 veliparib;cisplatin;vinorelbine tartrate
38 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
39 Clinical Trial of Trametes Versicolor in Women With Breast Cancer Completed NCT00680667 Phase 1
40 Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32 Unknown status NCT01666171 metformin hydrochloride
41 Study of Tumor and Blood Samples From Women With Breast Cancer Unknown status NCT00897728
42 Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer Completed NCT00900133
43 Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer Completed NCT00870168 Not Applicable chemotherapy
44 TC Avastin. ICORG 08-10, V6 Completed NCT00911716 Not Applicable cyclophosphamide;docetaxel
45 Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer Completed NCT00115505
46 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases Completed NCT00072293 Not Applicable
47 Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer Completed NCT00755313 aromatase inhibition therapy;carboplatin;cyclophosphamide;docetaxel;doxorubicin hydrochloride
48 Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer Completed NCT00068328
49 Assessment of Candidate Protein Expression in Breast Cancer Specimens Recruiting NCT00918892
50 Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer Terminated NCT00503841 Not Applicable erlotinib hydrochloride

Search NIH Clinical Center for Estrogen-Receptor Negative Breast Cancer

Genetic Tests for Estrogen-Receptor Negative Breast Cancer

Anatomical Context for Estrogen-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Negative Breast Cancer:

41
Breast, Brain, Lymph Node, Bone, T Cells, Colon, Endothelial

Publications for Estrogen-Receptor Negative Breast Cancer

Articles related to Estrogen-Receptor Negative Breast Cancer:

(show top 50) (show all 185)
# Title Authors Year
1
Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data. ( 29518546 )
2018
2
Associations between Diet Quality Scores and Risk of Postmenopausal Estrogen Receptor-Negative Breast Cancer: A Systematic Review. ( 29378048 )
2018
3
Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women. ( 29141994 )
2017
4
AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients. ( 28238761 )
2017
5
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. ( 29058716 )
2017
6
Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. ( 28263391 )
2017
7
WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells. ( 28469783 )
2017
8
Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. ( 29087320 )
2017
9
PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer. ( 28881566 )
2017
10
Toll-like receptor 4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women. ( 28280355 )
2017
11
Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. ( 28957356 )
2017
12
Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit I^-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer. ( 29069648 )
2017
13
Jim Crow and estrogen-receptor-negative breast cancer: US-born black and white non-Hispanic women, 1992-2012. ( 27988896 )
2017
14
Targeting Aberrant p70S6K Activation for Estrogen Receptor Negative Breast Cancer Prevention. ( 28877935 )
2017
15
Effect of 17I^-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model. ( 29133279 )
2017
16
Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer. ( 27167193 )
2016
17
Is estrogen receptor negative breast cancer risk associated with a fast life history strategy? ( 26781544 )
2016
18
Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II. ( 27294610 )
2016
19
Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer. ( 27328114 )
2016
20
Prognostic significance of Claudin 12 in estrogen receptor-negative breast cancer. ( 26926102 )
2016
21
Genome-wide Association Studies in Women of African Ancestry Identified 3q26.21 as a Novel Susceptibility Locus for Estrogen Receptor Negative Breast Cancer. ( 27594435 )
2016
22
A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines. ( 26648459 )
2016
23
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. ( 28039445 )
2016
24
Estrogen stimulated migration and invasion of estrogen receptor-negative breast cancer cells involves an ezrin-dependent crosstalk between G protein-coupled receptor 30 and estrogen receptor beta signaling. ( 26850467 )
2016
25
The Circadian Rhythm Gene Arntl2 Is a Metastasis Susceptibility Gene for Estrogen Receptor-Negative Breast Cancer. ( 27656887 )
2016
26
Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor-Negative Breast Cancer. ( 27431462 )
2016
27
Life history theory and breast cancer risk: methodological and theoretical challenges: Response to "Is estrogen receptor negative breast cancer risk associated with a fast life history strategy?". ( 26874356 )
2016
28
Effect of sodium/iodide symporter (NIS)-mediated radioiodine therapy on estrogen receptor-negative breast cancer. ( 25955347 )
2015
29
NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer. ( 26351264 )
2015
30
Induction of apoptosis and oxidative stress in estrogen receptor-negative breast cancer, MDA-MB231 cells, by ethanolic mango seed extract. ( 25881293 )
2015
31
Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. ( 25852060 )
2015
32
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 26621491 )
2015
33
Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women. ( 26085483 )
2015
34
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. ( 25849327 )
2015
35
Interleukin-8 upregulates integrin I^3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-I_B pathway. ( 25979232 )
2015
36
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 25720324 )
2015
37
Nitric Oxide-Releasing Aspirin Suppresses NF-I_B Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo. ( 26184135 )
2015
38
N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation. ( 26279450 )
2015
39
Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells. ( 26220629 )
2015
40
Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status. ( 26339363 )
2015
41
In Vitro and In Silico Evaluation of NF-I_B Targeted Costunolide Action on Estrogen Receptor-Negative Breast Cancer Cells-A Comparison with Normal Breast Cells. ( 24733523 )
2014
42
Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach. ( 24678876 )
2014
43
A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer. ( 25417701 )
2014
44
Expression of autophagy-related proteins according to androgen receptor and HER-2 status in estrogen receptor-negative breast cancer. ( 25140630 )
2014
45
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. ( 24829621 )
2014
46
A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. ( 24523857 )
2014
47
Associations between estrogen receptor-negative breast cancer and timing of reproductive events differ between African American and European American women. ( 24718280 )
2014
48
Expression of Reactive Oxygen Species-Related Proteins according to Androgen and HER-2 Status in Estrogen Receptor-Negative Breast Cancer. ( 25322848 )
2014
49
The prevalence of estrogen receptor-negative breast cancer in Ethiopia. ( 25433805 )
2014
50
Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status. ( 24850180 )
2014

Variations for Estrogen-Receptor Negative Breast Cancer

Expression for Estrogen-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Negative Breast Cancer.

Pathways for Estrogen-Receptor Negative Breast Cancer

GO Terms for Estrogen-Receptor Negative Breast Cancer

Biological processes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.87 AR BRCA1 ESR1 ETS1 FOXA1 PGR
2 positive regulation of protein kinase B signaling GO:0051897 9.8 EGF ERBB2 ESR1
3 positive regulation of canonical Wnt signaling pathway GO:0090263 9.79 CCAR2 EGF WNT5A
4 male gonad development GO:0008584 9.76 AR ESR1 WNT5A
5 phosphatidylinositol phosphorylation GO:0046854 9.75 EGF ERBB2 ESR1
6 response to estradiol GO:0032355 9.73 ESR1 ETS1 FOXA1
7 positive regulation of transcription, DNA-templated GO:0045893 9.73 AR BRCA1 EGF ESR1 ETS1 WNT5A
8 positive regulation of angiogenesis GO:0045766 9.67 BRCA1 CXCL8 ETS1 WNT5A
9 steroid hormone mediated signaling pathway GO:0043401 9.63 AR ESR1 PGR
10 dopaminergic neuron differentiation GO:0071542 9.62 FOXA1 WNT5A
11 uterus development GO:0060065 9.6 ESR1 WNT5A
12 negative regulation of ERBB signaling pathway GO:1901185 9.59 EGF ERBB2
13 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.55 AR FOXA1
14 positive regulation of transcription by RNA polymerase III GO:0045945 9.54 AR ERBB2
15 vagina development GO:0060068 9.52 ESR1 WNT5A
16 prostate gland epithelium morphogenesis GO:0060740 9.49 AR FOXA1
17 positive regulation of cell-cell adhesion mediated by cadherin GO:2000049 9.48 FOXA1 WNT5A
18 epithelial cell proliferation involved in mammary gland duct elongation GO:0060750 9.43 ESR1 WNT5A
19 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.4 AR PGR
20 lateral sprouting involved in mammary gland duct morphogenesis GO:0060599 9.16 AR WNT5A
21 mammary gland alveolus development GO:0060749 9.13 AR EGF ESR1
22 positive regulation of gene expression GO:0010628 9.1 AR BRCA1 EGF ERBB2 ETS1 WNT5A
23 regulation of transcription, DNA-templated GO:0006355 10.17 AR BRCA1 CCAR2 ERBB2 ESR1 ETS1
24 transcription, DNA-templated GO:0006351 10.11 AR BRCA1 CCAR2 ERBB2 ESR1 ETS1
25 regulation of transcription by RNA polymerase II GO:0006357 10.08 AR BRCA1 ERBB2 ESR1 ETS1 FOXA1

Molecular functions related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 DNA binding transcription factor activity GO:0003700 9.93 AR ESR1 ETS1 FOXA1 PGR WNT5A
2 sequence-specific DNA binding GO:0043565 9.88 AR ESR1 ETS1 FOXA1 PGR
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.83 AR ESR1 ETS1 PGR
4 transcription factor binding GO:0008134 9.8 AR ESR1 ETS1 FOXA1
5 transcription regulatory region DNA binding GO:0044212 9.71 AR BRCA1 FOXA1 WNT5A
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.69 EGF ERBB2 PTPRA
7 ATPase binding GO:0051117 9.61 AR ESR1 PGR
8 enzyme binding GO:0019899 9.55 AR BRCA1 CCAR2 ESR1 PGR
9 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.54 EGF ERBB2 ESR1
10 steroid hormone receptor activity GO:0003707 9.5 AR ESR1 PGR
11 nuclear receptor activity GO:0004879 9.43 AR ESR1 PGR
12 steroid binding GO:0005496 9.13 AR ESR1 PGR
13 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.02 AR ESR1 ETS1 FOXA1 PGR
14 protein binding GO:0005515 10.35 AR BRCA1 CCAR2 CXCL8 CYB5R3 EGF

Sources for Estrogen-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....